학술논문
EE15 Cost-Consequence Analysis of Ofatumumab in Comparison With Other Disease-Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
Document Type
Abstract
Author
Source
In Value in Health December 2022 25(12) Supplement:S55-S56
Subject
Language
ISSN
1098-3015